Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals (Nasdaq: PCSA) has announced that Dr. David Young, Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 in Boston. The presentation, scheduled for April 24, 2025, at 2:00 p.m. ET, will focus on 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases'.
Dr. Young will discuss how Project Optimus principles can be utilized to determine optimal dosing for improved efficacy and safety in rare disease treatments, both oncological and non-oncological. This approach aligns with Processa's Regulatory Science strategy, which aims to enhance therapeutic outcomes through improved regulatory science methodologies.
Processa Pharmaceuticals (Nasdaq: PCSA) ha annunciato che il dott. David Young, fondatore e presidente della Ricerca e Sviluppo, presenterà al World Orphan Drug Congress USA 2025 a Boston. La presentazione, prevista per il 24 aprile 2025 alle 14:00 ET, sarà incentrata su 'Applicazione dei principi del Project Optimus della FDA alle malattie rare oncologiche e non oncologiche'.
Il dott. Young illustrerà come i principi di Project Optimus possano essere utilizzati per determinare il dosaggio ottimale, migliorando efficacia e sicurezza nei trattamenti delle malattie rare, sia oncologiche che non oncologiche. Questo approccio è in linea con la strategia di Regulatory Science di Processa, che mira a migliorare i risultati terapeutici attraverso metodologie avanzate di scienza regolatoria.
Processa Pharmaceuticals (Nasdaq: PCSA) ha anunciado que el Dr. David Young, fundador y presidente de Investigación y Desarrollo, presentará en el World Orphan Drug Congress USA 2025 en Boston. La presentación, programada para el 24 de abril de 2025 a las 2:00 p.m. ET, se centrará en 'Aplicación de los principios del Proyecto Optimus de la FDA en enfermedades raras oncológicas y no oncológicas'.
El Dr. Young explicará cómo los principios del Proyecto Optimus pueden utilizarse para determinar la dosis óptima, mejorando la eficacia y seguridad en los tratamientos de enfermedades raras, tanto oncológicas como no oncológicas. Este enfoque está alineado con la estrategia de Ciencia Regulatoria de Processa, que busca mejorar los resultados terapéuticos mediante metodologías avanzadas en ciencia regulatoria.
Processa Pharmaceuticals (나스닥: PCSA)는 연구개발 창립자이자 사장인 Dr. David Young이 보스턴에서 열리는 World Orphan Drug Congress USA 2025에서 발표할 예정이라고 발표했습니다. 발표는 2025년 4월 24일 오후 2시(동부시간)에 예정되어 있으며, 'FDA의 Project Optimus 원칙을 종양 및 비종양 희귀질환에 적용하기'에 초점을 맞출 것입니다.
Young 박사는 Project Optimus 원칙이 종양 및 비종양 희귀질환 치료에서 효능과 안전성을 개선하기 위한 최적 용량 결정에 어떻게 활용될 수 있는지 논의할 예정입니다. 이 접근법은 향상된 규제 과학 방법론을 통해 치료 결과를 개선하고자 하는 Processa의 규제 과학 전략과 일치합니다.
Processa Pharmaceuticals (Nasdaq : PCSA) a annoncé que le Dr David Young, fondateur et président de la Recherche & Développement, présentera au World Orphan Drug Congress USA 2025 à Boston. La présentation, prévue le 24 avril 2025 à 14h00 ET, portera sur « Application des principes du Project Optimus de la FDA aux maladies rares oncologiques et non oncologiques ».
Le Dr Young expliquera comment les principes du Project Optimus peuvent être utilisés pour déterminer la dose optimale afin d'améliorer l'efficacité et la sécurité des traitements des maladies rares, qu'elles soient oncologiques ou non. Cette approche s'inscrit dans la stratégie de Regulatory Science de Processa, qui vise à améliorer les résultats thérapeutiques grâce à des méthodologies avancées en sciences réglementaires.
Processa Pharmaceuticals (Nasdaq: PCSA) hat bekannt gegeben, dass Dr. David Young, Gründer und Präsident der Forschung & Entwicklung, auf dem World Orphan Drug Congress USA 2025 in Boston präsentieren wird. Die Präsentation ist für den 24. April 2025 um 14:00 Uhr ET geplant und behandelt das Thema 'Anwendung der Prinzipien von FDAs Project Optimus bei onkologischen und nicht-onkologischen seltenen Krankheiten'.
Dr. Young wird erörtern, wie die Prinzipien von Project Optimus genutzt werden können, um die optimale Dosierung zur Verbesserung von Wirksamkeit und Sicherheit bei der Behandlung seltener Krankheiten, sowohl onkologischer als auch nicht-onkologischer Art, zu bestimmen. Dieser Ansatz entspricht der Regulatory-Science-Strategie von Processa, die darauf abzielt, therapeutische Ergebnisse durch verbesserte regulatorische Wissenschaftsmethoden zu optimieren.
- None.
- None.
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.
Dr. Young’s presentation, titled “Applying Principles of FDA’s Project Optimus to Oncology and Non-Oncology Rare Diseases,” will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center.
Dr. Young’s presentation will explore how the principles of FDA’s Project Optimus initiative — particularly determining the optimal dose to improve the balance of efficacy and safety — can be used for the FDA approval of drugs to treat rare oncology and rare non-oncology diseases. This approach is core to Processa’s Regulatory Science approach, which focuses on improving therapies through regulatory science to deliver better outcomes for patients.
For more information about World Orphan Drug Congress USA 2025, please click here.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
FAQ
When is Dr. David Young presenting at the World Orphan Drug Congress USA 2025 for PCSA?
What is the topic of Processa Pharmaceuticals' (PCSA) presentation at the 2025 World Orphan Drug Congress?
How does PCSA's presentation align with their company strategy?
What is the main focus of Processa Pharmaceuticals' (PCSA) research and development?
Where will PCSA's presentation at the World Orphan Drug Congress 2025 take place?
